Search results
Results From The WOW.Com Content Network
The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. [9] [10] It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. [11]
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. [1] Symptoms typically start anywhere between two days and three weeks after infection. [3] The first symptoms are usually fever, sore throat, muscle pain, and headaches. [1]
A stockpile of half-a-million Ebola vaccine doses was established by Gavi and other global health partners in 2019 for use in outbreaks of haemorrhagic fever, which has an average fatality rate of ...
The 2018 Équateur province Ebola outbreak occurred in the north-west of the Democratic Republic of the Congo (DRC) from May to July 2018. It was contained entirely within Équateur province, and was the first time that vaccination with the rVSV-ZEBOV Ebola vaccine had been attempted in the early stages of an Ebola outbreak, [6] with a total of 3,481 people vaccinated.
Many Ebola vaccine candidates had been developed in the decade before 2014, but none has yet been approved for clinical use in humans. [211] Several promising vaccine candidates have been shown to protect nonhuman primates (usually macaques) against lethal infection, and some are now going through the clinical trial process. [212] [213]
In December 2016, it was announced that an experimental Ebola vaccine produced by Merck was found to be "highly protective" against the virus after trial runs involving 11,000 people in Guinea. [187] Previously, a 2015 study in medical journal The Lancet reported that the vaccine was 100 percent effective after tests on 4000 people in Guinea ...